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Background: Carbapenem resistant Enterobacteriaceae (CRE) is increasingly reported worldwide. A similar increase is
seen in Singapore since identification of its first case in 2008. The aim of this study was to identify local risk factors
for carriage of CRE in patients from an acute tertiary care hospital in Singapore.
Method: A matched case-control study was conducted on inpatients treated from January 1, 2011 till December
31, 2013. Two hundred and three cases of CRE infection or colonization were matched with 203 controls. CRE types
were identified by PCR. Statistical analysis of data including a multivariate logistic regression analysis was done using
SPSS 21.0.
Results: CREs were commonly seen in Klebsiella pneumoniae (42.2 %), Escherichia coli (24.3 %) and Enterobacter
cloacae complex (17.2 %) in the 268 isolates. NDM-1 was the commonest CRE type seen (44.4 %), followed by KPC
(39.9 %) whilst OXA-48 only constituted (7.8 %). Univariate analysis identified key risk factors associated with CRE as
history of previous overseas hospitalization (OR: 33.667; 95 % CI: 4.539-259.700), admission to ICU (OR: 11.899; 95 %
CI: 4.986-28.399) and HD/ICA (OR: 6.557; 95 % CI: 4.057-10.596); whilst a multivariate analysis revealed exposure to
antibiotics penicillin (OR: 4.640; 95 % CI: 1.529-14.079] and glycopeptide (OR: 5.162; 95 % CI: 1.377-19.346) and presence of
central line device (OR: 3.117; 95 % CI: 1.167-8.330) as significant independent predictors.
Conclusions: The identification of risk factors amongst our local population helped to refine the criteria used for target
active surveillance screening for CRE amongst inpatients at time of hospital admission.
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Carbapenem resistant Enterobacteriaceae (CRE) is in-
creasingly reported worldwide with increasing awareness
of the global problem and improved methods of labora-
tory identification. Following the report of the emer-
gence of the New Delhi metallo-β-lactamase-1 (NDM-1)
in India, Pakistan, and the United Kingdom in 2010,
there has also been much worldwide interest and con-
cern of its increased epidemiology and potential impact
on patient care. In Asia, Klebsiella pneumoniae Carbape-
nemase (KPC) was first detected in China in 2004 [1],
and subsequently in South Korea and Taiwan [2, 3]. In* Correspondence: ling.moi.lin@sgh.com.sg
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creativecommons.org/publicdomain/zero/1.0/Singapore, KPC was first reported in 2012 [4] where two
of the four patients had strains closely related to the
Chinese strain but the other two patients were non-
Chinese with no travel history. The authors suggested
possible community dissemination of KPC.
Shortly after the first discovery of the first NDM-1 pa-
tient at the Singapore General Hospital (SGH) in 2008,
we noticed a steady gradual rise in the number of CRE
patients in the subsequent years [5, 6]. This has signifi-
cant implication on care of some of our patients requir-
ing intermediate long term care (ILTC) management as
some ILTCs were reluctant to receive CRE patients due
to limited isolation facilities. Healthcare associated infec-
tions associated with multidrug resistant Gram negative
bacilli have been shown to incur higher financial costs;le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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by public funding in the form of governmental subven-
tion in Singapore [7]. Moreover, there is also the risk of
potential nosocomial CRE outbreaks arising from envir-
onmental contamination or lapses in infection control
practices [8–11]. In light of these challenges and the fact
that there are limited therapeutic options for the man-
agement of patients with CRE infections, we conducted
a case-control study with the main objectives of identify-
ing risk factors for carriage of CRE in our patients and
enhancing existing strategies in controlling the spread of
CRE amongst inpatients at our hospital.
Methods
Study design and population
We conducted a matched case-control study to identify
risk factors associated with the acquisition of CRE
amongst inpatients treated at SGH, a 1700-bed tertiary
acute care hospital in Singapore. Cases were adults over
age 18 years, whom CRE were isolated from clinical cul-
tures from any source between January 1, 2011 and
December 31, 2013. For each CRE patient, one control
was randomly selected from adult inpatients admitted
within the study period matched for gender, age, without
CRE isolates. Subjects with CRE isolated from multiple
sites or on multiple dates were counted only once where
information from first event was collected as a case.
Data collection
Data were extracted from the patients’ medical records and
from hospital computerized databases according to a pre-
prepared questionnaire. Variables analyzed as possible pre-
dictors included demographics (age, gender, ethnic group,
ward class), specific co-morbid conditions (cardiovascular,
renal, diabetes mellitus, malignancy, transplantation, etc.),
length of stay, history of admission from overseas hospital
in the past one year, history of admission in the past one
year, history of overseas travel in the past one year, admis-
sions to intensive care unit (ICU), high dependency or
intermediate care area (HD or ICA), invasive procedures,
surgical procedures, presence of other multidrug resistant
organisms (MDROs), invasive devices (within one month
prior to CRE) and exposure (≥1 day(s)) to antimicrobials
(imipenem, meropenem, ertapenem, doripenem, ciproflox-
acin, vancomycin, cephalosporins, piperacillin-tazobacatam,
metronidazole), and radiation therapy (deep x-ray therapy
DXT) (within one month prior to CRE identification).
Microbiological methods
Carbapenem susceptibility was determined using disk
diffusion and interpreted in accordance to the 2009
Clinical and Laboratory Standards Institute guidelines as
per hospital’s clinical microbiology laboratory protocol.
Carbapenemase-producing CRE were then identifiedusing the modified Hodge test and the Roscoe test. Their
CRE types were confirmed by the National Public Health
Laboratory using the polymerase chain reaction (PCR)
method.
Data analysis
The association of categorical variables with CRE pa-
tients was first examined using Χ2or Fisher exact test
and Odds ratio (ORs) analysis with corresponding 95 %
confidence intervals (CIs) computed. For continuous
data, Student t tests and Mann-Whitney U tests were
applied appropriately. A multivariate logistic regression
analysis evaluated the independent contribution of the
variables if p < 0.1, adjusted for total length of hospital
stay. Statistical significance was considered when p was
less than 0.05. Statistical analyses were performed using
SPSS 21.0(SPSS, Chicago, IL, USA).
Results
Demographic data
Two hundred and three cases of CRE infection or
colonization were identified between 1 January 2011–31
December 2013 and matched with 203 controls. The dis-
tributions of age, race, gender and ward classes are
shown in Table 1.
The common CRE isolated from 203 patients were
Klebsiella pneumoniae (42.2 %), Escherichia coli (24.3 %)
and Enterobacter cloacae complex (17.2 %). The cases
were non-gender bias in the 32–96 years old age group
with distribution as Chinese (66.0 %), Malay (14.3 %), In-
dian (7.9 %) and others (11.8 %). Average length of stay
before the patient was identified with CRE was 21.1 ±
40.5 days.
Isolation sites and types of CRE
The distribution of isolation sites of the 268 isolates are
shown in Fig. 1. CRE was commonly isolated from stool/
rectal swab (61.6 %), urine (13.1 %) and other clinical
sites (25.3 %). NDM-1 was the commonest CRE type
seen (44.4 %), followed by KPC (39.9 %) whilst OXA-48
only constituted 7.8 % (Fig. 2).
Risk factor analysis
The mean total length of hospital stay is significantly
longer in CRE cases than controls (48.0 vs 3.9 days,
p < 0.001). Significant risk factors of the univariate ana-
lysis were summarized in Table 2. Higher proportions of
CRE cases had an exposure to health care with history of
previous overseas hospitalization (OR: 33.667; 95 %
CI: 4.539–259.700), admission to ICU (OR: 11.899;
95 % CI: 4.986–28.399) and HD/ICA (OR: 6.557; 95 %
CI: 4.057–10.596), with need for urinary catheter (OR:
4.239; 95 % CI: 2.630–6.831), drains (OR: 3.146; 95 %
CI: 1.534–6.450) and enteral feeding (OR: 5.554; 95 %
Table 1 Demographic details of CRE patients and control patients
Demographic CP-CRE patients Control Standards X-value
(N = 203) (N = 203) (p-value)
n (%) n (%) n (%) (case vs. standards)
Mean age ± SD (years) 64.3 ± 16.0 64.0 ± 15.7 - -
(mean years 95 % confidence interval) (62.1–66.5) (61.9–66.2)
Gender
Male 113 (55.7 %) 113 (55.7 %) 1,891,500 (49.2 %)[a] 3.331
Female 90 (44.3 %) 90 (44.3 %) 1,953,200 (50.8 %)[a] (0.068)
Paying class
(based on collection ward)
Class A 16 (7.9 %) 26 (12.8 %) 5696 (7.2 %)[b]
Class B1/B1+ 20 (9.9 %) 15 (7.4 %) 9050 (11.5 %)[b] 9.086
Class B2 86 (42.4 %) 77 (37.9 %) 32,048 (40.8 %)[b] (0.028)*
Class C 81 (39.9 %) 85 (41.9 %) 24,028 (30.6 %)[b]
Ethnic group
Chinese 134 (66.0 %) 133 (72.7 %) 2,853,800 (74.2 %)[a]
Malay 29 (14.3 %) 32 (17.5 %) 512,800 (13.3 %)[a] 5.437
Indian 16 (7.9 %) 16 (8.7 %) 351,700 (9.1 %)[a] (0.142)
Others (Singaporean) 1 (0.5 %) 2 (1.1 %) 126,500 (3.3 %)[a]
Others: Bangladeshi 7 (3.4 %) 1 (0.5 %) - -
Others: Burmese 1 (0.5 %) 1 (0.5 %) - -
Others: Chinese 1 (0.5 %) 4 (1.9 %) - -
Others: Indian 2 (1.0 %) 2 (1.0 %) - -
Others: Indonesian 4 (1.9 %) 4 (1.9 %) - -
Others: Malaysian 2 (1.0 %) 0 (0 %)
Others: Oman 1 (0.5 %) 0 (0 %)
Others: Pakistani 2 (1.0 %) 0 (0 %)
Others: Qatar 0 (0 %) 1 (0.5 %) - -
Others: Thai 0 (0 %) 1 (0.5 %) - -
Others: UAE 0 (0 %) 2 (1.0 %)
Others: Vietnamese 3 (1.5 %) 3 (1.5 %) - -
*p < 0.05 (Significance of association; 2-tailed)
aDepartment of Statistics Singapore, 2013, Population Trends 2013
bSGH Bulletin Beds in Service by Ward and Bed Class (2013)
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lant upon arrival (OR: 0.337; 95 % CI: 0.221–0.513), and
more likely to have comorbidities such as cardiovascular
disease (OR: 1.868; 95 % CI: 1.256–2.778) and hematology
conditions (OR: 4.328; 95 % CI: 1.592–11.769). They were
also exposed to immunosuppressive treatments of DXT
(OR: 2.230; 95 % CI: 1.057–4.706) and steroid (OR: 3.202;
95 % CI: 1.606–6.384). CRE cases were also exposed to a
variety of antibiotics classes which included β-lactam/
β-lactamase inhibitor combinations (OR: 3.676; 95 %
CI: 2.432–5.557) and fluoroquinolones (OR: 2.018;
95 % CI: 1.111–3.663). In addition, CRE cases harbored
other MDROs: MRSA (OR: 2.051; 95 % CI: 1.213–
3.468) and VRE (OR: 7.411; 95 % CI: 2.825–19.441) andwere exposed to invasive procedures of bronchoscopy
(OR: 6.047; 95 % CI: 2.045–17.881).
The results for the multivariate analysis were presented
in Table 3. Upon adjustment for total length of hospital
stay, exposure to antibiotics penicillin (OR: 4.640; 95 %
CI: 1.529–14.079] and glycopeptide (OR: 5.162; 95 %
CI: 1.377–19.346) and presence of central line device
(OR: 3.117; 95 % CI: 1.167–8.330) emerged as signifi-
cant independent predictors associated with CRE.
Outcomes
There were 37 (18.2 %) mortalities amongst the CRE
cases. CRE cases had ~3.5 times odds of fatality ad-
justed for length of hospital stay (adjusted OR: 3.532;
Fig. 1 Distribution of CRE by isolation sites
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No outbreak was noted during the study period.
Discussion
Interestingly, the results of our case-control study re-
vealed different risk factors from other investigators.
Twenty-nine of our 203 cases (85.7 %) had no history of
overseas travel in the past 90 days before admission and
had no previous overseas hospitalization. Hence, it is
likely that CRE is already in our community setting.
Our study identified similar risk factors that other in-
vestigators have highlighted-exposure to antimicrobials,
especially carbapenems and fluoroquinolones [12–15],





















Fig. 2 Carbapenemase types isolated[17] e.g. central line, urinary catheter, endotracheal tube
and the enteral feeding tube. In addition, our study iden-
tified unique risk factors viz. hematology patients and
those with immunodeficiency. This may be explained by
the recurring admissions and discharges as well as a
relatively longer length of stay in this patient population
exposing them to greater risk than the general patient
population.
Our multivariate analysis showed similar findings with
other investigators [18, 19] that antimicrobial usage, in-
creased risk for CRE colonization. Penicillin use was as-
sociated with increased risk for CRE colonization among
patients admitted to the hospital, as in our study. From




Table 2 Univariate analysis of risk factors associated with CRE carriage
Risk factors CP-CRE patients Control X = value/Mann-Whitney U Odds Ratio
(N = 203) (N = 203) (p-value/Fisher Exact) [95 % Cl]
n (%) n (%)
Total length of stay ± SD 48.0 ± 59.5 3.9 ± 3 8 U: 3223 1.266 [1.197–1.340]
(days) (39.8–56.3) (3.4–4.5) (<0.001) (<0.001)
(moan days 95 % confidence interval)
History of previous overseas hospitalisation 29 (14.3 %) 1 (0.5 %) 28.218 (<0.001)** 33.667 [4.539–259.700]
History of travelling in past 90 days 29 (14.3 %) 15 7.4 %) 4.996 (0.025)* 2.089 [10.83.4.028]
Ambulant on arrival 103 (50.7 %) 153 (75.4 %) 26.432 (<0.001)** 0.337 [0.221–0.513]
Admission to CU 54 (26.6 %) 6 (3.0 %) 45.059 (<0.001)** 11.899 [4.986–28.399]
Mean ICU stay ± SD, day 9.6 ± 12.2 1.2 ± 1.0 U: 46.0 (<0.004)** -
(mean days 95 % confidence interval) (6.3—13.0) (0.1—2.2)
Admission to HD/ICA 106 (52.2 %) 29 (14.3 %) 65.797 (<0.001)** 6.557 [4.057–10.596]
Mean HD/ICA stay ± SD, day 5.3 ± 6.1 2.0 ± 1.7 9.0 (0.372) -
(mean days 95 % confidence interval) (4.1–6.5) (1.4–2.7)
Cardiovascular disease comorbidity 105 (51.7 %) 74 (36.5 %) 9.602 (0.002)** 1.868 [1.256–2.778]
Diabetes mellitus comorbidity 67 (33.0 %) 58 (28.6 %) 0.936 (0.333) 1.232 [0.807–1.870]
Malignancy cormorbidity 57 (28.1 %) 41 (20.2 %) 3.443 (0.064) 1.543 [0.974–2.442]
Immunodeficiency comorbidity 10 (4.9 %) 2 (1.0 %) 5.496 (0.019)* 5.207 [1.126–24.072]
Haematology comorbidity 20 (9.9 %) 5 (2.5 %) 9.591 (0.002)** 4.328 [1.592–11.769]
Exposure to DXT 23 (11.3 %) 11 (5.4 %) 4.622 (0.032)* 2.230 [1.057–4.706]
Exposure to steroid 34 (16.7 %) 12 (5.9 %) 11.866 (0.001)** 3.202 [1.606–6.384]
Exposure to chemotherapy 15 (7.4 %) 16 (7.9 %) 0.035 (0.852) 0.933 [0.448–1.941]
Exposure to penicillin antibiotics 33 (16 3 %) 7 (3.4 %) 18.747 (<0.001)** 5.435 [2.344–12.604]
Exposure to β-lactam/β-lactamase inhibitor
combinations antibiotics
122 (60.1 %) 59 (29.1 %) 39.568 (<0.001)** 3.676 [2.432–5.557]
Exposure to cephalosporin antibiotics 65 (32.0 %) 43 (21.2 %) 6.106 (0.013)* 1.753 [1.120–2.742]
Exposure to carbapenems antibiotics 62 (30.5 %) 5 (2.5 %) 58.077 (<0.001)** 17.413 [6.826–44.417]
Exposure to fluoroquinolones antibiotics 35 (17.2 %) 19 (9.4 %) 5.468 (0.019)* 2.018 [1.111–3.663]
Exposure to glycopeptide antibiotics 69 (34.0 %) 4 (2.0 %) 70.564 (<0001)** 25.618 [9.132–71.865]
Exposure to metronidazole antibiotics 36 (17.7 %) 15 (7.4 %) 9.889 (0.002)** 2.702 [1.428–5.110]
Exposure to aminoglycosides antibiotics 17 (8.4 %) 1 (0.5 %) 14.882 (<0.001)** 18.462 [2433–140,097]
Presence of central line device 80 (39.4 %) 11 (5.4 %) 67.433 (<0.001)** 11.353 [5.811–22.179]
Presence of urinary catheter device 86 (42.4 %) 30 (14.8 %) 37.842 (<0.001)** 4.239 [2.630–6.831]
Presence of ETT device 42 (20.7 %) 6 (3.0 %) 30.620 (<0.001)** 8.565 [3.55 1–20.658]
Presence of intra-arterial line device 24 (11.8 %) 5 (2.5 %) 13.406 (<0.001)** 5.309 [1.984–14.2 11]
Presence of drains device 31 (15.3 %) 11 (5.4 %) 10.623 (0.001)** 3.146 [1.534–6.450]
Presence of enteral feeding device 49 (24.1 %) 11 (5.4 %) 28.240 (<0.001)** 5.554 [2.793–11.044]
Presence of additional MRSA 47 (23.2 %) 26 (12.8 %) 7.365 (0.007)** 2.051 [1.213–3.468]
Presence of additional VRE 32 (15.8 %) 5 (2.5 %) 21.678 (<0.001)** 7.411 [2.825-19.441]
Exposure to bronchoscopy procedure 22 (10.8 %) 4 (2.0 %) 13.314 (<0.001)** 6.047 [2.045–17.881]
Exposure to gastroscopy procedure 18 (8.9 %) 10 (4.9 %) 2.455 (0.117) 1.878 [0.845–4.175]
Exposure to colonoscopy procedure 4 (2.0 %) 6 (3.0 %) 0.410 (0.522) 0.660 [0.183–2.375]
Exposure to angiogram procedure 9 (4.4 %) 6 (3.0 %) 0.623 (0.430) 1.523 [0.532–4361]
Underwent surgery 141 (69.5 %) 146 (71.9 %) 0.297 (0.586) 1.126 [0.734–1.727]
*p < 0.05 (Significance of association; 2-tailed), **p < 0.01 (Significance of association; 2-tailed)
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Table 3 Multivariate analysis of risk factors
Risk factor (Multivariable model) Adjusted Odds Ratio
[95 % Confidence Interval]
(Sig)
Exposure to antibiotics penicillin 4.640 [1.529–14.079] (0.007)*
Exposure to antibiotics glycopeptides 5.162 [1.377–19.346] (0.015)**
Presence of central line device 3.117 [1.167–8.330] (0.023)**
*p < 0.01; **p < 0.05 (Significance of association; 2-tailed)
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pressure (CVP) line. Indwelling devices are recognised
risk factors for healthcare-associated infections [20, 21].
Hence, it is not surprising to see the presence of a CVP
line as an independent risk factor for CRE infection.
This highlights the importance of safe patient care prac-
tices especially in the care of devices as well as the sig-
nificance of an antimicrobial stewardship program in the
strategy for the prevention of CRE infections.
We conducted a preliminary data analysis for risk fac-
tors from the 2011–2012 data and identified criteria for
active surveillance for CRE as part of an effort to reduce
the incidence of CRE. From January 2013, the criteria
used were history of overseas travel in the past one year,
transfers from overseas hospital and history of admis-
sions to private hospitals in Singapore in past one year.
This was modified to include admissions to ICU, high
dependency units and intermediate care units (October
2013); renal (March 2014), haematology (April 2014),
oncology (June 2014). Since then, our healthcare-
associated CRE has stabilized to 0.28 per 1000 patient
days (2014) from previous rates of 0.03 and 0.26 respect-
ively (2012, 2013). We were able to institute prompt
isolation and control measures upon knowing the active
surveillance screening results. This helped to prevent
horizontal transmission between patients in our general
wards, where most patients are housed in open wards
with 4–8 beds in a cubicle.
Our study has several limitations. Firstly, CRE was
identified from clinical specimens submitted to the
Microbiology Laboratory. Active surveillance for CRE
carriage was not done during 2011–2012 and the CRE
carriage rate could have been higher than found. Sec-
ondly, because active surveillance for CRE was not done
at admission, we were not able to determine if the pa-
tients had acquired it during their inpatient stay. A case
control study involving multiple centers or over a longer
period may help to overcome the problem of small sam-
ple size. Our study is underpowered at 47.4 % (α: 0.05)
as we only had 203 patients in each arm. For power to
be at 80 %, we would need 855 patients in each arm
[22]. This study investigated the risk factors for being
colonized with CRE in our patient population. Acquisi-
tion was not studied as exit swabs were not done forthose who had entry screening swabs done. Hence, it
will not be possible to correlate the link between the risk
factors and acquisition.Conclusions
The global increase in CRE in many healthcare facilities
poses challenges to infection control and infectious dis-
ease professionals. Risk-based screening is one strategy
that has been used to limit the spread of CRE in health-
care settings [18, 19, 23]. We have demonstrated the
value of understanding local epidemiology to help mod-
ify our risk-based screening as a strategy to limit the
spread of CRE. Hence, we recommend targeted screen-
ing strategies to identify patients colonized with CRE at
the time of admission to a healthcare institution as a
component of a CRE reduction program.
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